Alvin Shih

Alvin is an experienced biopharma executive with more than 15 years of clinical and drug development experience, encompassing the full spectrum from discovery/translational to post-marketing programs. He has worked in multiple therapeutic modalities, including cell/tissue therapy, enzyme replacement, and small molecule approaches. Alvin is a rare disease specialist with a successful track record in building and managing complex organizations to accomplish end-to-end drug development. Alvin was most recently President and CEO of Disarm Therapeutics. Prior to Disarm Therapeutics, he was CEO of Enzyvant Therapeutics, a development-stage biotechnology company. Prior to Enzyvant, he was Executive Vice President and Head of R&D at Retrophin, where he managed the development and progress of a diverse pipeline encompassing rare neurological and renal diseases. Earlier in his career, he was a founding member of Pfizer’s rare disease research unit. He was also previously a management consultant for L.E.K. Consulting and McKinsey & Company.

Alvin holds an M.D. from the University of Alabama and an MBA from the Kellogg School of Management at Northwestern University. He completed his residency training in internal medicine at Massachusetts General Hospital.